BCM
TEVA icon

Bourgeon Capital Management’s Teva Pharmaceuticals TEVA Stock Holding History

Bourgeon Capital Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.11M Sell
268,970
-17,287
-6% -$576K 1.34% 34
2026
Q1 		$8.62M Sell
286,257
-325,088
-53% -$10.5M 1.49% 34
2025
Q4 		$19.1M Sell
611,345
-108,655
-15% -$2.68M 3.09% 5
2025
Q3 		$14.5M Sell
720,000
-3,974
-0.5% -$69.8K 2.63% 10
2025
Q2 		$12.1M Buy
723,974
+363,252
+101% +$5.86M 2.39% 15
2025
Q1 		$5.54M Sell
360,722
-299,233
-45% -$5.35M 1.19% 37
2024
Q4 		$14.5M Sell
659,955
-3,366
-0.5% -$61.2K 2.72% 8
2024
Q3 		$12M Sell
663,321
-5,015
-0.8% -$87.8K 2.3% 15
2024
Q2 		$10.9M Buy
668,336
+3,244
+0.5% +$50K 2.13% 19
2024
Q1 		$9.38M Buy
665,092
+6,447
+1% +$81.3K 1.84% 22
2023
Q4 		$6.88M Sell
658,645
-2,968
-0.4% -$27.7K 1.52% 28
2023
Q3 		$6.75M Buy
661,613
+9,853
+2% +$91.7K 1.58% 29
2023
Q2 		$4.91M Buy
+651,760
New +$5.28M 1.14% 36
2017
Q2 		– Sell
-7,350
Closed -$236K – 92
2017
Q1 		$236K Sell
7,350
-48,475
-87% -$1.65M 0.15% 73
2016
Q4 		$2.02M Sell
55,825
-14,275
-20% -$570K 1.27% 32
2016
Q3 		$3.23M Buy
70,100
+3,900
+6% +$203K 2.07% 23
2016
Q2 		$3.33M Buy
66,200
+11,650
+21% +$620K 2.16% 21
2016
Q1 		$2.92M Sell
54,550
-1,600
-3% -$93.9K 1.95% 25
2015
Q4 		$3.69M Buy
56,150
+100
+0.2% +$6.18K 2.37% 16
2015
Q3 		$3.17M Buy
56,050
+4,600
+9% +$298K 2.21% 16
2015
Q2 		$3.04M Sell
51,450
-12,450
-19% -$768K 1.84% 21
2015
Q1 		$3.98M Sell
63,900
-1,300
-2% -$75.6K 2.44% 11
2014
Q4 		$3.75M Sell
65,200
-100
-0.2% -$5.57K 2.29% 16
2014
Q3 		$3.51M Buy
65,300
+50
+0.1% +$2.65K 2.05% 15
2014
Q2 		$3.42M Buy
65,250
+4,700
+8% +$240K 1.86% 16
2014
Q1 		$3.2M Buy
+60,550
New +$2.8M 2.02% 16

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Bourgeon Capital Management's TEVA Position: Q2 2026 in Review

Bourgeon Capital Management reduced its Teva Pharmaceuticals (TEVA) stake by 6% in Q2 2026, selling an estimated $576K and leaving 268,970 shares worth $9.11M. The position accounts for 1.34% of the portfolio, ranked #34.

Bourgeon Capital Management first reported a position in TEVA in Q1 2014 and has held it in 26 quarters since. The position peaked at $19.1M in Q4 2025. 672 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

  • Bourgeon Capital Management held 268,970 shares of Teva Pharmaceuticals worth $9.11M as of Q2 2026.
  • Bourgeon Capital Management sold 17,287 Teva Pharmaceuticals shares in Q2 2026, an estimated $576K.
  • Teva Pharmaceuticals made up 1.34% of Bourgeon Capital Management's portfolio in Q2 2026, its #34 holding.
  • Bourgeon Capital Management first reported a position in Teva Pharmaceuticals in Q1 2014 and has held it in 26 quarters since.
  • Bourgeon Capital Management's Teva Pharmaceuticals position peaked at $19.1M in Q4 2025.
  • 672 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Bourgeon Capital Management's 13F filing for Q2 2026, filed 22 Jul 2026.